UY39106A - Agonistas de gpr40 - Google Patents
Agonistas de gpr40Info
- Publication number
- UY39106A UY39106A UY0001039106A UY39106A UY39106A UY 39106 A UY39106 A UY 39106A UY 0001039106 A UY0001039106 A UY 0001039106A UY 39106 A UY39106 A UY 39106A UY 39106 A UY39106 A UY 39106A
- Authority
- UY
- Uruguay
- Prior art keywords
- agonists
- gpr40 agonists
- disorder
- gpr40
- nash
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 title abstract 4
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000007149 gut brain axis pathway Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000030212 nutrition disease Diseases 0.000 abstract 1
- 208000019180 nutritional disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983438P | 2020-02-28 | 2020-02-28 | |
| US202063076113P | 2020-09-09 | 2020-09-09 | |
| US202063117074P | 2020-11-23 | 2020-11-23 | |
| US202163147982P | 2021-02-10 | 2021-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39106A true UY39106A (es) | 2021-09-30 |
Family
ID=77490353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039106A UY39106A (es) | 2020-02-28 | 2021-03-01 | Agonistas de gpr40 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230151037A1 (https=) |
| EP (1) | EP4110760A4 (https=) |
| JP (1) | JP2023528713A (https=) |
| CN (1) | CN115867536A (https=) |
| AU (1) | AU2021225966A1 (https=) |
| CA (1) | CA3173732A1 (https=) |
| TW (1) | TW202140424A (https=) |
| UY (1) | UY39106A (https=) |
| WO (1) | WO2021174046A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4337202A4 (en) | 2021-06-18 | 2025-04-02 | Aligos Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| EP4448512A4 (en) | 2021-12-16 | 2025-11-19 | Aligos Therapeutics Inc | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| CN118724767A (zh) * | 2023-03-28 | 2024-10-01 | 南京华狮新材料有限公司 | 一种氨基酸衍生物及其制备方法和作为中间体合成l-草铵膦的方法 |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| WO2025136929A1 (en) * | 2023-12-19 | 2025-06-26 | Kallyope, Inc. | Gpr40 agonists |
| WO2025137310A1 (en) * | 2023-12-22 | 2025-06-26 | Kallyope, Inc. | Crystalline gpr40 agonist and methods of making |
| WO2026019701A1 (en) * | 2024-07-15 | 2026-01-22 | Venenum Biodesign, LLC | Substituted phenylsulfonamides as mgat2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558585C (en) * | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US8119617B2 (en) * | 2006-08-23 | 2012-02-21 | Novartis Ag | aSMase inhibitors |
| RU2627703C2 (ru) * | 2010-07-23 | 2017-08-10 | Конекшис Лайф Сайенсиз Пвт. Лтд. | Агонисты gpr40 |
| WO2013122028A1 (ja) * | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| EP3076959B1 (en) * | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) * | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| TW201613878A (en) * | 2014-07-09 | 2016-04-16 | Janssen Pharmaceutica Nv | Pyrazine GPR40 agonists for the treatment of type II diabetes |
| US20220226298A1 (en) * | 2019-05-29 | 2022-07-21 | Kallyope, Inc. | Gpr40 agonists |
-
2021
- 2021-02-26 WO PCT/US2021/019973 patent/WO2021174046A1/en not_active Ceased
- 2021-02-26 CN CN202180031973.XA patent/CN115867536A/zh active Pending
- 2021-02-26 CA CA3173732A patent/CA3173732A1/en active Pending
- 2021-02-26 JP JP2022551555A patent/JP2023528713A/ja active Pending
- 2021-02-26 AU AU2021225966A patent/AU2021225966A1/en not_active Abandoned
- 2021-02-26 TW TW110106878A patent/TW202140424A/zh unknown
- 2021-02-26 EP EP21759537.0A patent/EP4110760A4/en not_active Withdrawn
- 2021-02-28 US US17/802,910 patent/US20230151037A1/en not_active Abandoned
- 2021-03-01 UY UY0001039106A patent/UY39106A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021174046A1 (en) | 2021-09-02 |
| AU2021225966A1 (en) | 2022-09-15 |
| TW202140424A (zh) | 2021-11-01 |
| CN115867536A (zh) | 2023-03-28 |
| EP4110760A4 (en) | 2024-09-18 |
| JP2023528713A (ja) | 2023-07-06 |
| EP4110760A1 (en) | 2023-01-04 |
| US20230151037A1 (en) | 2023-05-18 |
| CA3173732A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39107A (es) | Agonistas de gpr40 | |
| UY39106A (es) | Agonistas de gpr40 | |
| CL2022000856A1 (es) | Agonistas de gpr119 | |
| UY38976A (es) | Antagonistas de sstr5 | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| MX2021012492A (es) | Agonistas de glp-1r y usos de los mismos. | |
| CO2019006917A2 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| GT201700143A (es) | Derivado de biarilo como agonista de gpr120 | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CL2008000017A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci | |
| ECSP088407A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| CL2008000018A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci | |
| HN2011001759A (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| MX2010005243A (es) | Composiciones corticosteroides. | |
| MX2011006625A (es) | Regimen de dosificacion de un agonista de los receptores de s1p. | |
| EA200900877A1 (ru) | Пиперидиновые агонисты gpcr | |
| NO20091260L (no) | Kombinasjonsbehandling for diabetes mellitus | |
| RU2013158109A (ru) | Хирургический инструмент | |
| AR076935A1 (es) | Mecanismo de reajuste para un dispositivo para entrega de farmaco | |
| Ghobadi et al. | A review on the structures and biological activities of anti-Helicobacter pylori agents | |
| CL2022003208A1 (es) | Activadores de la ampk | |
| BR112012027648A2 (pt) | composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto | |
| MX2024004994A (es) | Métodos para tratar el cáncer de ovário con extracto de cáñamo. | |
| PE20120909A1 (es) | Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma | |
| MX2022011089A (es) | Peptidos como agonistas selectivos del receptor de gip. |